8.1 Cytotoxic drugs

National Patient Safety Agency (NPSA) Rapid response alert - Risks of incorrect dosing of oral anti-cancer medicine (January 2008)

This alert is only focusing on patients who receive treatment for a malignancy. It does not include patients who receive cytotoxics for treatment of rheumatoid arthritis or other auto-immune diseases.

The NPSA is alerting all healthcare staff involved in the use of oral anti-cancer medicines of potentially fatal outcomes if incorrect doses of these medicines are used. Oral anti-cancer medicines are increasingly being used in hospitals and in the community. Risks are increased if non-specialist practitioners prescribe, dispense or administer these oral medicines and bypass the normal safeguards used for injectable anti-cancer medicines.

Full information: www.npsa.nhs.uk/corporate/news/patient-safety-risks-of-incorrect-dosing-of-oral-anti-cancer-medicines

 

Home > Formulary > Chapters > 8. Immunomodulatory treatments and malignant disease > 8.1 Cytotoxic drugs

 

  • First line
  • Second line
  • Specialist
  • Hospital